Leading global vaccine products by market share 2017 and 2024

Prevnar 13, a pneumococcal vaccine developed by Pfizer and Daewoong, is projected to account for roughly 13 percent of the global vaccine market in 2024. While the product’s share would be considerably lower when compared to 2017, it is expected to remain the top vaccine product on the market. The global vaccine market Global vaccine revenue is expected to increase significantly for a number of pharmaceutical giants, such as GlaxoSmithKline, Merck & Co, Sanofi, and Pfizer. GSK’s vaccine-based revenue, for example, is forecast to grow by almost 40 percent between 2017 and 2024. Sanofi vaccines In 2018, Sanofi generated roughly close to 25 billion U.S. dollars through its pharmaceuticals segment, which is the company’s largest segment by far. Over five billion U.S. dollars were generated through the company’s vaccine division that year. Between 2016 and 2018, the company’s highest-yielding vaccines were for diseases, such as polio, pertussis, as well as influenza.

辉瑞公司和德威龙公司共同研发的肺炎球菌疫苗Prevnar 13，预计将在2024年占据全球疫苗市场的约13%。尽管与2017年相比，其市场份额显著降低，但预计仍将稳居市场主导地位。全球疫苗市场预计将显著增长，对多家制药巨头，如葛兰素史克（GSK）、默克公司（Merck & Co）、赛诺菲（Sanofi）和辉瑞公司等，疫苗收入都将实现显著提升。以GSK为例，其基于疫苗的收入预计将在2017年至2024年间增长近40%。赛诺菲疫苗在2018年，通过其制药部门创造了约250亿美元的收入，这一部门是该公司的最大业务板块。当年，其疫苗部门贡献了约50亿美元的收入。在2016年至2018年间，公司收入最高的疫苗主要针对脊髓灰质炎、百日咳以及流感等疾病。